The CoreValve™ Evolut™ PRO valve is a next evolution transcatheter aortic valve featuring an advanced design to help with valve sealing performance to address the occurrence of blood leaking through the sides of the valve.

Approved by the U.S. Food and Drug Administration in March 2017, the self-expanding device is intended to treat patients with severe aortic stenosis who are considered at high or extreme risk for open-heart surgery.

**Advanced Sealing with Outer Wrap**
The Evolut PRO valve was designed with an outer porcine biocompatible pericardial tissue wrap that adds surface area contact between the valve and the native aortic annulus to further advance valve sealing performance.

**Lowest True Delivery Profile**
The Evolut PRO System is delivered through the EnVeo™ R Delivery Catheter System and is indicated for vessels down to 5.5 mm.

**Proven Clinical Performance**
Built on the superior platform of the CoreValve TAVR System and the recapturable Evolut R System, the Evolut PRO valve features all the clinical advantages of the predicate platform, including a self-expanding nitinol frame that helps achieve excellent hemodynamic performance and the ability to position and deploy the Evolut PRO device with greater control.